Clinical trial • Phase I • Oncology

GEN1106 for Metastatic solid tumors | Advanced malignant solid tumors

Phase I trial of GEN1106 for Metastatic solid tumors | Advanced malignant solid tumors. 53 participants.

Overview

Trial Therapeutic Area
Oncology
Trial Disease
Metastatic solid tumors | Advanced malignant solid tumors
Trial Stage
Phase I

Key dates

Initial CTIS Submission Date
09-01-2026
First CTIS Authorization Date
27-04-2026

Trial design

Phase I trial across 5 sites in Spain.

Target Sample Size
53

Eligibility

Recruits 53 Vulnerable population selected; no details on consent or assent processes provided in the available record..

Vulnerable Population
Vulnerable population selected; no details on consent or assent processes provided in the available record.

Recruitment

Planned Sample Size
53
Recruitment Window Months
30

Geography

Total Number Of Sites
5
Total Number Of Participants
53

Spain

Earliest CTIS Part Ii Submission Date
24-03-2026
Latest Decision Or Authorization Date
27-04-2026
Processing Time Days
34
Number Of Sites
5
Number Of Participants
50

Sites

Site Name
Hospital Universitario Quironsalud Madrid
Department Name
NEXT Oncology
Contact Person Name
Valentina Boni
Contact Person Email
vboni@nextoncology.eu
Site Name
Hospital Hm Nou Delfos
Department Name
START
Contact Person Name
Tatiana Hernandez Guerrero
Site Name
Hospital Universitario Fundacion Jimenez Diaz
Department Name
START
Contact Person Name
Ester Garcia Lorenzo
Contact Person Email
ester.garcia@startmadrid.com
Site Name
Hospital Universitari Vall D Hebron
Department Name
Oncology - Phase I
Contact Person Name
Elena Garralda Cabanas
Contact Person Email
egarralda@vhio.net
Site Name
Hospital Universitario Hm Sanchinarro
Department Name
START
Contact Person Name
Juan Francisco Rodriguez Moreno

Sponsor

Primary sponsor

Full Name
Genmab A/S
Organisation Type
Pharmaceutical company
Country Of Registered Address
Denmark

Investigational products

Investigational Product Name
GEN1106

Related trials

Other published trials that may interest you.